Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 43 CNY -4.04%
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Acrobiosystems Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Total Current Liabilities
ÂĄ185.1m
CAGR 3-Years
99%
CAGR 5-Years
79%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Total Current Liabilities
ÂĄ1.4B
CAGR 3-Years
100%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Liabilities
ÂĄ1.6B
CAGR 3-Years
27%
CAGR 5-Years
41%
CAGR 10-Years
32%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
27%
CAGR 5-Years
32%
CAGR 10-Years
71%
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
48.56 CNY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Total Current Liabilities?
Total Current Liabilities
185.1m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Total Current Liabilities amounts to 185.1m CNY.

What is Acrobiosystems Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
79%

Over the last year, the Total Current Liabilities growth was 75%. The average annual Total Current Liabilities growth rates for Acrobiosystems Co Ltd have been 99% over the past three years , 79% over the past five years .

Back to Top